Hypothalamic hormones and cancer

Frontiers in Neuroendocrinology

Volumn 22, Issue 4, 2001, Pages 248-291

  Schally, A V ^a,b   Comaru Schally, A M ^a,b   Nagy, A ^a,b   Kovacs, M ^a,b   Szepeshazi, K ^a,b   Plonowski, A ^a,b   Varga, J L ^a,b   Halmos, G ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Agonists and antagonists of LH RH; Bombesin antagonists; GH RH antagonists; Somatostatin analogs; Targeted cytotoxic analogs; Tumor therapy

Indexed keywords

BOMBESIN; BOMBESIN ANTAGONIST; BOMBESIN RECEPTOR; CYTOTOXIC AGENT; GASTRIN RELEASING PEPTIDE; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; HYPOTHALAMUS HORMONE; PEPTIDE DERIVATIVE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

CANCER; CELL PROLIFERATION; CYTOTOXICITY; DRUG TARGETING; ENDOCRINE TUMOR; HORMONE ACTION; HYPOPHYSIS GONAD SYSTEM; ISOTOPE LABELING; METASTASIS; PRIORITY JOURNAL; REVIEW; TUMOR LOCALIZATION;

EID: 0034771199     PISSN: 00913022     EISSN: None     Source Type: Journal    
DOI: 10.1006/frne.2001.0217     Document Type: Article

References (160)

1. Neuroendocrine differentiation and hormone refractory prostate cancer
2. Peptide hormone and serotonin immunoreactive cells in normal and hyperplastic prostate glands
3. Somatostatinoma: Atypical presentation of a rare pancreatic tumor
4. Use of somatostatin analogue octreotide to localise and manage somatostatin-producing tumors
5. Neuroendocrine differentiation and the bombesin/gastrin releasing peptide family of neuropeptides in the progression of human prostate cancer
6. New antagonists of LHRH: II. Inhibition and potentiation of LHRH by closely related analogues
7. SMS 201-995: A very potent and selective octapeptide analogue of somatostatin with prolonged action
8. Androgen receptor status in endocrine-paracrine cell types of the normal hyperplastic and neoplastic human prostate
9. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone
10. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone
11. Thyrotropin-secreting pituitary tumors: Diagnostic criteria, thyroid hormone sensitivity and treatment outcome in 25 patients followed at the National Instituters of Health
12. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2
13. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by SSTR2 and SSTR5 somatostatin receptor subtypes through different mechanisms
14. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer
15. 2 or its derivatives
16. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin
17. Aberrant expression of gastrin releasing peptide and its receptor by well differentiated colon cancers in humans
18. Correlation between the effects of bombesin antagonists on cell proliferation and intracellular calcium concentration in Swiss 3T3 and HT-29 cell lines
19. Identification, characterization and biological activity of specific receptors for natural (Ghrelin) and synthetic growth hormone secratagogues and analogs in human breast carcinomas and cell lines
20. Effective treatment of metastatic MDA-MD-435 human estrogen independent breast carcinomas with a targeted cytotoxic analog of luteinizing hormone-releasing hormone, AN-207
21. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit growth of OV-1063 human epithelial ovarian ca. cell line xenografted into nude mice
22. Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa
23. Gonadotropin-releasing hormone receptors: Characterization, physiological regulation and relationship to reproductive functions
24. Efficacy and safety of luteinizing hormone-releasing hormone antagonist Cetrorelix in the treatment of syruptomatic benign prostatic hyperplasia
25. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue
26. Androgen receptor activation in prostatic tumor cell lines by insulin like growth factor
27. Synergistic activation of androgen receptor by androgen and luteinizing hormone releasing hormone in prostatic carcinoma cells
28. Bombesin-like peptides can function as autocrine growth factors in human small cell lung cancer
29. Neuroendocrine differentiation in carcinoma of the prostate
30. Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: Evidence for an autocrine-inhibitory LHRH loop
31. Long-acting lanreotide induces clinical and biochemical remission of acromegaly caused by disseminated growth hormone-releasing hormone secreting carcinoid
32. Effects of LHRH-analogues on mitogenic signal transduction in cancer cells
33. High affinity binding and direct antiproliferative effects of LH-RH analogues in human ovarian cancer cell lines
34. Luteinizing hormone-releasing hormone agonist triptorelin in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer - A prospective double blind randomized trial
35. The use of luteinizing hormone releasing hormone agonists and antagonists in gynecological cancers
36. 6]luteinizing hormone-releasing hormone, somatostatin, epidermal growth factor and sex steroids in 500 biopsy samples of human breast cancer
37. Ectopic adrenocorticotropic hormone
38. Neuroendocrine systems
39. Ectopic production of growth hormone-releasing factor by carcinoid and pancreatic islet tumors associated with acromegaly
40. A new treatment for endometrial cancer with gonadotropin-releasing hormone analogue
41. Prognostic values of neuroendocrine differentiation in prostate cancer
42. Luteinizing hormone-releasing hormone antagonist SB-75 (Cetrorelix)as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord
43. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer
44. Gastrin releasing peptide receptors in non neoplastic human breast
45. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly
46. High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers
47. Cytotoxic analogs of luteinizing hormone-releasing hormone bind with high-affinity to human breast cancers
48. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095
49. Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone (LH-RH) in OV-1063 human epithelial ovarian cancers during therapy with LH-RH antagonist Cetrorelix
50. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers
51. Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone
52. Human ovarian cancers express somatostatin receptors
53. Characterization of bombesin/GRP receptors in human breast cancer and their relationship to steroid receptor expression
54. Glucagonoma, VIPoma, somatostatinoma, other hormones, and nonfunctional tumors
55. Expression of the messenger ribonucleic acids for luteinizing hormone-releasing hormone and its receptor in human ovarian epithelial carcinoma
56. Expression of luteinizing hormone-releasing hormone and its mRNA in human endometrial cancer cell lines
57. Suppression of growth hormone (GH) hypersecretion due to ectopic GH-releasing hormone (GHRH) by a selective GHRH antagonist
58. Androgen independent growth is induced by neuropeptides in human prostate cancer cell lines
59. Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II
60. Inhibition of growth of CAKI-I human renal adenocarcinoma in vivo by LH-RH antagonist Cetrorelix, somatostatin analog RC-160 and bombesin antagonist RC-3940-II
61. Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin
62. Growth hormone-releasing hormone (GH-RH) antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma
63. Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone
64. Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers
65. Complete regression of MX-1 human breast cancer xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207
66. Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice
67. Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238
68. Inhibition of growth of MDA-MB-468 estrogen independent human breast cancers by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3095 and RC-3940-II
69. Antagonists of growth hormone Releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice
70. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: Rationale and perspective
71. Administration of LH-releasing hormone to selected human subjects
72. Chronic somatostatin analog administration in patients with α-subunit-secreting pituitary tumors
73. The German Zoladex trial group: Goserelin, a depot gonadotropin releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer
74. Targeted cytotoxic analog of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice
75. Regression of U-87 MG human glioblastoma in nude mice after treatment with a cytotoxic somatostatin analog AN-238
76. A targeted cytotoxic somatostatin analogue AN-238 inhibits growth of H-69 small cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice
77. Inhibition of growth of human malignant glioblastoma in nude mice by antagonists of bombesin/gastrin-releasing peptide
78. Growth hormone-releasing hormone: An autocrine growth factor for small cell lung carcinoma
79. Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study
80. Ghrelin is a growth hormone releasing acylated peptide from stomach
81. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma
82. Targeted cytotoxic analogue of somatostatin AN-238 inhibits the growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses
83. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice
84. Luteinizing hormone-releasing hormone (LH-RH) antagonist Cetrorelix down-regulates the mRNA expression of pituitary receptors for LHRH by counteracting the stimulatory effect of endogenous LHRH
85. Regulation of targeted chemotherapy with cytotoxic LH-RH analog by epidermal growth factor
86. 3]octreotide: The Rotterdam experience with more than 1,000 patients
87. Somatostatin analogue scintigraphy in carcinoid tumors
88. The role of somatostatin and its analogues in the diagnosis and treatment of tumors
89. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of Insulin Like Growth Factor II in tumors
90. Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP
91. The luteinizing hormone-releasing hormone-secreting hypothalamic hamartoma is a congenital malformation: Natural history
92. Gastrin-releasing peptide receptors in the human prostate: Relation to neoplastic transformation
93. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence
94. New technique for quantitation of pituitary adenoma size: Use in evaluating treatment of gonadotroph adenomas with a gonadotropin-releasing hormone antagonist
95. Acromegaly
96. Gonadotropin-releasing hormone messenger RNA expression in gonadotrop tumors and normal human pituitary
97. Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095
98. Growth inhibition of human ovarian cancers by cytotoxic analogues of luteinizing hormone-releasing hormone
99. Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits growth of OV-1063 human epithelial ovarian cancers in nude mice
100. Suppression of plasma gonadotropins by Abarelix: A potent new LHRH antagonist
101. Design, synthesis, and in vitro evaluation of cytotoxic analogs of bombesin-like peptides containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin
102. Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent
103. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin
104. Suppression of follicular phase pituitarygonadal function by a potent new gonadotropin-releasing hormone antagonist with reduced histamine-releasing properties (ganirelix)
105. Corticotropin-releasing hormone in humans
106. Gastrin releasing peptide preferring bombesin receptors mediate growth of human renal cell carcinoma
107. Molecular pharmacology of somatostatin receptor subtypes
108. Chronic administration of luteinizing hormone-releasing hormone (LHRH) antagonist Cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats
109. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone
110. Inhibition of growth of human small-cell and non-small-cell lung carcinomas by antagonists of growth hormone-releasing hormone (GH-RH)
111. In vivo inhibition of PC-3 human androgen-independent prostate cancer by a targeted cytotoxic bombesin analogue AN-215
112. Inhibition of metastatic renal cell carcinomas expressing somatostatin receptors by a targeted cytotoxic analogue of somatostatin, AN-238
113. Inhibition of PC-3 human androgen-independent prostate cancer and its metastases by cytotoxic somatostatin analogue AN-238
114. Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasm potentially dependent on IGF-I
115. Mechanisms of antineoplastic action of somatostatin analogs
116. Inhibitory effect of bombesin receptor antagonist RC-3095 on the growth of human pancreatic cancer cells in vivo and in vitro
117. Somatostatin
118. Molecular biology of somatostatin receptors
119. Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers
120. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide
121. Somatostatin receptors in human renal cell carcinomas
122. Multiple actions of somatostatin in neoplastic disease
123. Characterization of a growth hormone-releasing factor from a human pancreatic islet tumor
124. 2 as a GRF antagonist on membranes
125. Endocrine treatment of breast cancer in women
126. Aspects of hypothalamic regulation of the pituitary gland
127. Oncological applications of somatostatin analogs
128. Hypothalamic hormones: From neuroendocrinology to cancer therapy
129. Luteinizing hormone-releasing hormone analogs: Their impact on the control of tumorigenesis
130. Isolation and properties of the FSH- and LH-releasing hormone
131. Gonadotropin-releasing hormone: One polypeptide regulates secretion of luteinizing and follicle-stimulating hormones
132. Hypothalamic and other peptide hormones
133. Peptide analogs in the therapy of prostate cancer
134. The actions of LH-RH agonists, antagonists, and cytotoxic analogs on the LH-RH receptors on the pituitary and tumors
135. Hypothalamic FSH and LH-regulating hormone, structure, physiology, and clinical studies
136. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors
137. Antagonistic analogs of growth hormone-releasing hormone: New potential antitumor agents
138. Gonadotropin-releasing hormone deficiency in the human (idiopathic hypogonadotropic hypogonadism, and Kallmann's syndrome): Pathophysiological and genetic considerations
139. Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice
140. Sex-specific expression of gastrin releasing peptide receptor: Relationship to smoking history and risk of lung cancer
141. Bombesin-like peptides: Of ligands and receptors
142. Humoral manifestations of malignancy
143. The presence of receptors for bombesin/gastrin-releasing peptide and mRNA for 3 receptor subtypes in human prostate cancers
144. The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers
145. Biology of disease, gastrin-releasing peptide (mammalian bombesin) gene expression in health and disease
146. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogues
147. Effect of combination treatment with analogs of luteinizing hormone-releasing hormone (LH-RH) or somatostatin and 5-fluorouracil on pancreatic cancer in hamsters
148. Antagonists of growth hormone-releasing hormone (GH-RH) decrease IGF-II production of HT-29 human colon cancer cells and inhibit tumour growth
149. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumors
150. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by bombesin & gastrin-releasing peptide antagonist RC-3095
151. A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers
152. Targeted cytotoxic luteinizing hormone releasing hormone (LH-RH) analogs inhibit growth of estrogen-independent MXT mouse mammary cancer in vivo by decreasing cell proliferation and inducing apoptosis
153. Small cell carcinoma of the prostate. I. A clinicopathologic study of 20 cases
154. Synthesis and biological evaluation of antagonists of growth hormone-releasing hormone with high and protracted in vivo activities
155. Bombesin may stimulate proliferation of human pancreatic cancer cells through an autocrine pathway
156. Receptor mediated antiproliferative effects of the cytotoxic LH-RH agonist AN-152 in human ovarian and endometrial cancer cell lines
157. Stimulation by bombesin and inhibition by bombesin/gastrin-releasing peptide antagonist RC-3095 of growth of human breast cancer cell lines
158. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75
159. Synthesis and biological activities of highly potent antagonists of growth hormone-releasing hormone